Navigation Links
New Biologics Must Show Improvements in Efficacy, Safety and Cost-Benefit Compared with Currently Available Agents for Inclusion on Formularies in Argentina, Brazil and Mexico
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that novel biologics must demonstrate improvements in efficacy, safety and cost-benefit compared with currently listed agents for a given disease to be included on both national and institutional formularies in Argentina, Brazil and Mexico. According to the new Strategic Insights report entitled Trends in Reimbursement of Biologics Across the Growth Markets: Focus on Argentina, Brazil and Mexico, numerous novel biological agents are in late-stage development for a range of oncology indications, rheumatoid arthritis and diabetes, and could reach these markets in the next two to three years.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The report notes that the market for biologics is lucrative, and growth in this sector will outpace the overall oncology and rheumatoid arthritis drug markets, resulting in an increase share of biologics in these markets.

"While approval from the regulatory bodies of Argentina, Brazil and Mexico may be reached shortly after a drug's approval in the major pharmaceutical markets, it may precede inclusion on formularies in these markets by several years," said Decision Resources Group Analyst Natalia Reoutova, M.A., M.Sc. "Historically, authorization was sufficient for market access terms but today, it's only one step toward favorable market access."

About Strategic Insights
Strategic Insights is a new series of high-level, strategic reports from Decision Resources Group thought leaders, designed for corporate executives in the biopharma industry. The Strategic Insights series evaluates global industry trends that are shaping the healthcare market, and delivers targeted, actionable insight in an easy-to-read PowerPoint format.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
2. Synthetic Biologics Announces Proposed Public Offering of Common Stock
3. Synthetic Biologics SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence
4. Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update
5. Synthetic Biologics to Report Third Quarter 2013 Financial Results
6. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
7. Samsung BioLogics unterzeichnet strategische Herstellungspartnerschaft mit Roche
8. Biosimilars Need Same Names as Original Biologics, Hospira Says at World Health Organization (WHO) Meeting
9. Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
10. Gallus Strengthens Biologics CMO Business with Acquisition of Laureate
11. Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
Breaking Biology Technology:
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
Breaking Biology News(10 mins):